IRIS
MENNA, PIERANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 717
NA - Nord America 457
EU - Europa 276
OC - Oceania 12
SA - Sud America 10
AF - Africa 5
Totale 1.477
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 482
US - Stati Uniti d'America 443
HK - Hong Kong 104
CN - Cina 87
GB - Regno Unito 80
CZ - Repubblica Ceca 54
DE - Germania 43
IT - Italia 40
IN - India 20
NL - Olanda 16
AU - Australia 12
CA - Canada 11
FI - Finlandia 11
BE - Belgio 6
BR - Brasile 6
UA - Ucraina 5
ZA - Sudafrica 5
JP - Giappone 4
TW - Taiwan 4
EE - Estonia 3
ID - Indonesia 3
PT - Portogallo 3
AL - Albania 2
AR - Argentina 2
AT - Austria 2
CL - Cile 2
FR - Francia 2
IE - Irlanda 2
MX - Messico 2
PK - Pakistan 2
PL - Polonia 2
TR - Turchia 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
ES - Italia 1
IQ - Iraq 1
KR - Corea 1
KZ - Kazakistan 1
LK - Sri Lanka 1
PH - Filippine 1
RO - Romania 1
RU - Federazione Russa 1
SA - Arabia Saudita 1
YE - Yemen 1
Totale 1.477
Salva come PNG Salva come JPEG
Città #
Singapore 180
Ashburn 120
Boardman 106
Hong Kong 102
London 76
Shanghai 55
Brno 35
Rome 25
Los Angeles 23
San Francisco 23
Redmond 20
Council Bluffs 18
Olomouc 17
Pune 17
Amsterdam 16
Munich 14
Helsinki 11
Washington 10
Santa Clara 9
Seattle 9
Toronto 8
Melbourne 6
Haikou 4
Canberra 3
Guangzhou 3
Hanover 3
Mol 3
Oklahoma City 3
Sydney 3
São Paulo 3
Taipei 3
Tokyo 3
Aversa 2
Dublin 2
Genoa 2
Hasselt 2
Lodz 2
New Delhi 2
North Liberty 2
Paris 2
Porto 2
Shenzhen 2
Tallinn 2
Tirana 2
West Jordan 2
Almaty 1
Ansan-si 1
Berlin 1
Brussels 1
Buenos Aires 1
Central District 1
Centurion 1
Charlotte 1
Chicago 1
Chongqing 1
Clifton 1
Colombo 1
Columbia 1
Dhaka 1
Frankfurt am Main 1
Guiyang 1
Hangzhou 1
Hefei 1
Hicksville 1
Hradec Králové 1
Kunming 1
Lisbon 1
Lomas de Zamora 1
Ma'anshan 1
Manila 1
Markham 1
Mexico City 1
Minsk 1
Naples 1
Nuremberg 1
Quilpué 1
Riyadh 1
Rockville 1
Sanaa 1
Sarajevo 1
Sona 1
Swansea 1
Vienna 1
Wuhan 1
Xingtai 1
Totale 997
Salva come PNG Salva come JPEG
Nome #
Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study 37
Anthracycline Cardiotoxicity 36
What is cardiotoxicity? 35
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology 33
CARDIAC ANTHRACYCLINE ACCUMULATION AND B-TYPE NATRIURETIC PEPTIDE TO DEFINE RISK AND PREDICTORS OF CANCER TREATMENT RELATED EARLY DIASTOLIC DYSFUNCTION 31
Anthracyclines 29
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach 26
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. 25
Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation: Implications for Cardiotoxicity of Anticancer Anthracyclines 25
Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium 24
Further analytical, pharmacokinetic, and clinical observations on low-dose ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 24
Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin 24
NEW TARGETED DRUGS FOR ACUTE MYELOID LEUKEMIA AND ANTIFUNGALS: PHARMACOKINETIC CHALLENGES AND OPPORTUNITIES 23
Anthracycline Cardiotoxicity 23
Pharmacology of Cardio-Oncology 23
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival 22
Low dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites 22
The endogenous lusitropic and chronotropic agent, B-type natriuretic peptide, limits cardiac troponin release in cancer patients with an early impairment of myocardial relaxation induced by anthracyclines 22
Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin 22
Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity 22
Altered iron regulatory protein activities in doxorubicin-treated cardiomyocytes : Distinct roles of reactive oxygen species and of the secondary alcohol metabolite doxorubicinol 22
Cardiotoxicity of targeted cancer drugs: concerns, “The cart before the horse,” and lessons from trastuzumab 22
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life 22
Development and Validation of a UHPLC-MS/MS-Based Method to Quantify Cenobamate in Human Plasma Samples 21
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 21
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox 21
Pharmacology of cardio-oncology: chronotropic and lusitropic effects of B-type natriuretic peptide in cancer patients with early diastolic dysfunction induced by anthracycline or nonanthracycline chemotherapy 20
4’- Epidoxorubicin to reexplore anthracycline degradation in cardiomyocytes 20
Anthracyclines and Cardiotoxicity: Is CARP a Forgotten Biomarker? 19
Isavuconazole: case report and pharmacokinetic considerations 19
Cardiotoxicity of antitumor drugs 19
An introduction to the metabolic determinants of anthracycline cardiotoxicity 19
Cardio-oncology in clinical studies and real life 19
Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial 19
Safety and tolerability of a novel oral nutritional supplement in healthy volunteers 19
Cancer drugs and QT prolongation: weighing risk against benefit 18
Matters of the heart: The case of TNF-alpha targeting drugs 18
Doxorubicinolone formation and efflux : A salvage pathway against epirubicin accumulation in human heart 18
Defective taxane stimulation of epirubicinol formation in the human heart: Insights into the cardiac tolerability of epirubicin-taxane chemotherapies 18
The concomitant management of cancer therapy and cardiac therapy 18
Doxorubicin irreversibly inactivates Iron Regulatory Proteins 1 and 2 in cardiomyocytes : Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy 18
Managing anthracycline-induced cardiotoxicity: beginning with the end in mind 17
Anthracycline metabolism and toxicity in human myocardyum: Comparisons between doxorubicin, epirubicin, and a novel disaccaride analogue with redeced formation and [4Fe-4S]-reactivity of its secondary alchol metabolite 17
Anthracyclines, diastolic dysfunction and the road to heart failure in Cancer survivors: An untold story 16
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies 16
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model I Amrubicin accumulates to a lower level than doxorubicin or epirubicin 16
Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue 16
Rethinking drugs from chemistry to therapeutic opportunities: Pixantrone beyond Anthracyclines. 16
MEN 10755 : A novel disaccharide anthracycline with a reduced level of formation and [4Fe-4S]-reactivity of toxic alcohol metabolite in human heart . 16
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: Relative importance of vesicular sequestration and impaired efficiency of electron addition 16
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin treated patients 15
Cardiovascular toxicity of antitumor drugs :Translating molecular mechanisms into clinical facts 15
Minimal sampling colistin pharmacokinetics in critically ill patients 15
Doxorubicin metabolism to toxic species in human myocardium: stimulation by paclitaxel and docetaxel but not BMS 184476 or BMS 188797 15
Doxorubicin degradation in cardiomyocytes 14
Pharmacological Foundation of Cardio-Oncology 14
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 14
Taxanes stimolate Doxorubicin conversion to its cardiotoxic secondary alcohol metabolite doxorubicinol: studies in human myocardium 14
MEN 10755: a novel disaccaride anthracycline with a reduced level of formation and [4Fe-4S]- reactivity of toxic alcohol metabolite in human myocardium 14
Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity 14
Ibrutinib and Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias/sudden cardiac death 14
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study 13
Role of secondary alcohol metabolites in anthracycline cardiotoxicity: from hypotheses to new drugs 13
In ®Entresto we trust 13
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin 13
The novel anthracycline MEN 10755 is less cardiotoxic than doxorubicin or epirubicin due to reduced formation and aconitase-reactivity its secondary alcohol metabolite 13
Doxorubicin dependent reduction of hypervalent ferrylmyoglobin: One more evidence against the oxidative nature of doxorubicin-induced cardiotoxicity 13
Recommendations for the harmonization of reference intervals in the therapeutic monitoring of antiepileptic drugs/Indicazioni per l’armonizzazione degli intervalli di riferimento nel monitoraggio terapeutico di farmaci antiepilettici 12
Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia 12
Tumour necrosis factor alpha (TNFα)cardiomyocyte preconditioning: clues to explain anti-TNFα agents contraindication in severe heart failure 12
Molecular determinants of the reduced cardiotoxicity of epirubicin 12
Tnf-alpha induced cardioprotection: effects on reactive oxygen species (ros) and apoptosis 12
Primary prevention strategies for anthracycline cardiotoxicity: a brief overview 11
Do you know pixantrone? 11
In vitro modelling of the structure-activity determinants of anthracycline cardiotoxicity. 11
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: relative importance of vesicular sequestration and impaired efficiency of electron addition J. Biol. Chem 11
Translating molecular mechanisms into clinical facts 11
Doxorubicin Cardiotoxicity and the Control of Iron Metabolism: Quinone-Dependent and Independent Mechanisms 11
Ferrylmyoglobin-dependent oxidative degradation of doxorubicin: a novel pathway of anthracycline metabolism and toxicity 11
Predictors of early or delayed diastolic dysfunction after anthracycline-based or nonanthracycline chemotherapy: a pharmacological appraisal 11
Quantitative Analysis of Cenobamate and Concomitant Anti-Seizure Medications in Human Plasma via Ultra-High Performance Liquid Chromatography–Tandem Mass Spectrometry 11
Modified colistin regimen for critically ill patients with acute renal impairment and continuous renal replacement therapy 10
Doxorubicin inhibits ferrylmyoglobin-dependent lipid peroxidation 10
Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment 10
Correction: Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN) 10
The reality of pixantrone in real life 9
Tumor necrosis factor alpha and cardiomyocytes: evidence for a self-protective preconditioning 9
Increasing doxorubicin antitumor activity through COX-2 inhibition without increasing cardiotoxicity 9
Taxanes stimulate doxorubicin conversion to its cardiotoxic secondary alcohol metabolite : Studies in human myocardium. 9
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis of ovarian origin 8
Humans and Rodents: The Case of hOAT4 and mOat5 7
High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study 6
Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN) 3
Totale 1.579
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.121
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.121
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022218 0 4 0 0 0 0 1 92 4 0 5 112
2022/202356 2 1 1 4 2 2 15 0 3 3 22 1
2023/2024333 6 35 11 15 37 146 1 16 2 8 4 52
2024/2025972 102 36 123 15 45 77 40 21 250 263 0 0
Totale 1.579